GlassScriptPhysician profile
Jonathan R Weiss
NPI 1417952052
$3,684.81
in general payments reported to CMS, 2019-2025
29 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $291 · 2021: $517 · 2022: $423 · 2023: $496 · 2024: $557 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349 · Travel and Lodging: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.68 |
| Travel and Lodging | $367.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $415.59 | 2019-2024 | Breztri, Airsupra |
| Mylan Specialty L.P. | $368.59 | 2019-2024 | Yupelri |
| Abbott Laboratories | $367.93 | 2025 | Tacticath Ablation Catheter, Sensor Enabled |
| Novo Nordisk INC | $341.45 | 2019-2024 | Saxenda, Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $319.14 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $275.76 | 2019-2023 | Xarelto |
| Pfizer INC. | $260.13 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.76 | 2019-2023 | Stiolto Respimat |
| Exact Sciences Corporation | $195.99 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $120.69 | 2019-2024 | Vraylar |
| Viatris Specialty LLC | $114.16 | 2025 | Yupelri |
| Amarin Pharma, INC. | $100.79 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $71.45 | 2019-2020 | |
| Astellas Pharma US INC | $59.86 | 2022-2024 | Veozah |
| Lilly USA, LLC | $51.99 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.25 | 2022-2023 | |
| Dexcom, INC. | $42.86 | 2023 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $42.61 | 2025 | Ohtuvayre |
| Allergan, INC. | $41.57 | 2019 | |
| Electromed, INC. | $40.94 | 2019-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $38.52 | 2019 | |
| Amgen INC. | $31.27 | 2019-2022 | |
| Insmed, INC. | $27.89 | 2025 | Brinsupri, Arikayce |
| Regeneron Healthcare Solutions, INC. | $23.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.48 | 2022 | |
| Grifols USA, LLC | $18.02 | 2022 | |
| Seqirus USA INC | $17.42 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.10 | 2021 | |
| Ani Pharmaceuticals, INC. | $13.57 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.